Embrex and Shenzhen Neptunus Interlong, P.R. China, Collaborate on Installation and Sale of Devices for Human Influenza Vaccine

RESEARCH TRIANGLE PARK, N.C., Aug. 1  /PRNewswire-FirstCall/ -- Embrex, Inc., The In Ovo Company(R), (NASDAQ:EMBX) has recently delivered to Shenzhen Neptunus Interlong Bio-technique Co. Ltd. (HKEx Stock Code 8329), Shenzhen, P.R. China ("SNI") an Egg Remover(R) system and an Inovoject (R) system. These have been installed in SNI's new state-of-the-art human influenza vaccine manufacturing facility at High-Tech Industrial Park Guangming, Shenzhen. Embrex will also provide regular service of the equipment.

The manufacturing facility, which has recently completed construction, is believed to be the largest and most advanced human influenza vaccine production facility in China. This follows on from SNI's successful IPO on the Hong Kong stock market in September 2005. The company was originally founded in 1994 and specializes in developing, producing and marketing bio-medicinal products from advanced biotechnology.

Before entering this collaboration with Embrex, SNI was able to consult with a number of the leading influenza vaccine manufacturers globally, many of whom have been using Embrex equipment for several years. These discussions confirmed the high quality of the equipment and service provided by Embrex, regardless of the location of the producer.

The high speed automated Egg Remover system identifies and removes, to a high degree of accuracy, infertile eggs and "early dead" embryos on days 9 to 11 of incubation. The viable eggs then proceed for inoculation with the influenza virus using the Inovoject system which injects eggs at a rate of approximately 30,000 eggs/hour. The Inovoject system has quality and process attributes which have made it a vital part of meeting the critical technical and regulatory needs of human flu vaccine producers in many countries, including a proprietary sanitation system which cleans needles after injection of every egg, thus minimizing cross-contamination between eggs.

Dr. David Baines, Vice President Global Sales & Marketing, Embrex commented that; "We are delighted to be working with SNI who clearly have a dedication to producing high quality vaccines and so wish to use the most advanced technology in all parts of their production process. We look forward to a long and close collaboration. This new installation in China is an example of the demands for equipment that we are seeing from many countries due to increasing egg-based flu vaccine production capacity to satisfy demands for both seasonal and pandemic flu vaccines."

Dr. Xiangdong Chai, Managing Director, SNI said "We have been very impressed by what we have seen and heard of the Embrex equipment and especially the service provided on an on-going basis, which we regard as vital in ensuring the success of our new venture."

About SNI

SNI is a high and new technology enterprise engaging in the R&D of modern biological technology, production and sale of cytokines category protein therapeutic drugs and biological products for disease prevention.

About Embrex

Embrex(R), Inc., The In Ovo Company(R), headquartered in Research Triangle Park, NC, is an international agricultural biotechnology company engaged in the development of innovative in ovo (in the egg) solutions that meet the needs of today's global poultry industry. The company's unique integration of several scientific and engineering disciplines enables it to be the leading provider of in ovo, value-added solutions with its automated injection and detection devices as well as its select vaccines. For additional information, visit the company web site at http://www.embrex.com/.

Statements in this release involve risks and uncertainties that could cause actual results to differ materially. Risks include without limitation the sporadic nature of device sales to human influenza vaccine manufacturers, the market acceptance and cost of expansion in new geographic markets and with new products, and the ability of Embrex's contract manufacturers to support such products. Additional risks include the Company's ability to penetrate new markets and the degree of market acceptance of the Company's products, the complete commercial development of potential future products on a cost effective basis, the availability of adequate supplies, and the ability to obtain regulatory approval of products. Such approval is dependent upon a number of factors, such as results of trials, the discretion of regulatory officials, and potential changes in regulations. Additional information on these risks and other factors, which could affect the Company's financial results, is included in the Company's Forms 10-K, 10-Q and other filings with the Securities and Exchange Commission.

Embrex(R), Inovoject(R), Egg Remover(R), and The In Ovo Company(R) are trademarks of Embrex, Inc.

Contact: Don Seaquist

Phone:   [phone] 

DATASOURCE: Embrex(R), Inc., The In Ovo Company(R)



CONTACT:  Don Seaquist of Embrex(R), Inc., The In Ovo Company(R),

Phone: [phone]



Web site:  http://www.embrex.com/

Copyright